Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir

被引:247
作者
Gubareva, LV
Kaiser, L
Matrosovich, MN
Soo-Hoo, Y
Hayden, FG
机构
[1] Univ Virginia, Sch Med, Dept Internal Med, Div Epidemiol & Virol, Charlottesville, VA 22908 USA
[2] Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA
[3] St Jude Childrens Res Hosp, Dept Virol & Mol Biol, Memphis, TN 38105 USA
[4] Russian Acad Med Sci, MP Chumakov Inst Poliomyelitis & Virus Encephalit, Moscow, Russia
关键词
D O I
10.1086/318537
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Volunteers experimentally infected with influenza A/Texas/36/91 (H1N1) virus and treated with the neuraminidase (NA) inhibitor oseltamivir were monitored for the emergence of drug-resistant variants. Two (4%) of 54 resistant viruses were detected by NA inhibition assay among last-day isolates recovered from 54 drug recipients. They bore a substitution His274Tyr in the NA. Hemagglutinin (HA) variants detected in the placebo group differed from the egg-adapted inoculum virus by virtue of amino acid substitutions at residues 137, 225, or both. These variants had a higher affinity for Neu5Ac(alpha2-6)Gal-containing receptors, which are characteristic of human respiratory epithelium, than for Neu5Ac(alpha2-3)Gal-containing receptors, which are typical of chicken egg allantoic membrane. Although appearing to be more sensitive to oseltamivir in humans, the variants with increased affinity for Neu5Ac(alpha2-6)Gal receptors were less sensitive than the Neu5Ac(alpha2-3)Gal-binding variants in Madin-Darby canine kidney cells. Thus, HA affinity for receptors is an essential feature of influenza virus susceptibility to NA inhibitors, both in cell culture and in humans.
引用
收藏
页码:523 / 531
页数:9
相关论文
共 42 条
  • [1] The HA1 of cold-adapted influenza B vaccine is not altered during replication in human vaccinees
    Abbasi, S
    Gruber, W
    Edwards, K
    Gubareva, L
    Webster, RG
    Kawaoka, Y
    [J]. VIRUS RESEARCH, 1995, 39 (2-3) : 377 - 383
  • [2] MUCINS AND MUCOIDS IN RELATION TO INFLUENZA VIRUS ACTION .6. GENERAL DISCUSSION
    ANDERSON, SG
    BURNET, FM
    GROTH, SFD
    MCCREA, JF
    STONE, JD
    [J]. AUSTRALIAN JOURNAL OF EXPERIMENTAL BIOLOGY AND MEDICAL SCIENCE, 1948, 26 (05): : 403 - 411
  • [3] Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140
    Bantia, S
    Ghate, AA
    Ananth, SL
    Babu, YS
    Air, GM
    Walsh, GM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (04) : 801 - 807
  • [4] BANTIA S, 2000, 13 INT C ANT RES BAL, pA60
  • [5] In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir
    Barnett, JM
    Cadman, A
    Burrell, FM
    Madar, SH
    Lewis, AP
    Tisdale, M
    Bethell, R
    [J]. VIROLOGY, 1999, 265 (02) : 286 - 295
  • [6] BAUM LG, 1990, ACTA HISTOCHEM, P35
  • [7] The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en
    Blick, TJ
    Sahasrabudhe, A
    McDonald, M
    Owens, IJ
    Morley, PJ
    Fenton, RJ
    McKimm-Breschkin, JL
    [J]. VIROLOGY, 1998, 246 (01) : 95 - 103
  • [8] Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en
    Blick, TJ
    Tiong, T
    Sahasrabudhe, A
    Varghese, JN
    Colman, PM
    Hart, GJ
    Bethell, RC
    McKimmBreschkin, JL
    [J]. VIROLOGY, 1995, 214 (02) : 475 - 484
  • [9] CARR J, 2000, 13 INT C ANT RES BAL, pA59
  • [10] RECEPTOR SPECIFICITY IN HUMAN, AVIAN, AND EQUINE H2 AND H3 INFLUENZA-VIRUS ISOLATES
    CONNOR, RJ
    KAWAOKA, Y
    WEBSTER, RG
    PAULSON, JC
    [J]. VIROLOGY, 1994, 205 (01) : 17 - 23